Pay in 4 interest-free payments of $5.85 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
Excellent for skin health, wound healing, and post-procedural recovery
Within the cognitive domain, the patient's cognitive functioning was commensurate with the level of moderate intellectual impairment (full scale intelligence quotient 43) at the age of 19;3 years
#Pfizer #NovoNordisk #Metsera #EliLilly #BiotechNews #PharmaDeals #HealthcareInnovation #PharmaNews #ObesityDrugs #GLP1 #Amylin #WeightLossMarket #LifeSciences #PharmaceuticalIndustry #DrugDevelopment #HealthcareTrends #BusinessStrategy #MergersAndAcquisitions #MetabolicHealth #ClinicalResearch #Biopharma #InvestmentNews #RAndD #MedicalInnovation #DrugDiscovery #BiotechInvesting #GlobalPharma #HealthcareBusiness #MarketWatch #InnovationInHealth To view or add a comment, sign in Pfizer has clinched a $10 billion deal for obesity drug developer Metsera, capping a fierce biotech bidding war between the New York-based pharma giant and Danish rival Novo Nordisk
PMID: 19558212
US$ 27.87
US$ 26.81
US$ 28.25
US$ 28.89
US$ 22.77
US$ 28.63
US$ 25.50
US$ 29.61
" loading="lazy"/>
